Imaging test that spots Trop2 protein in several solid tumors
Tests a Trop2-targeted PET scan to find solid tumors in adults.
Plain-language title generated from the registry record
Registry title: Trop2-targeted immunoPET Imaging of Solid Tumors
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2/3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a confirmed or suspected solid tumor who can have a special PET/CT scan using a Trop2-targeted imaging agent.
- Age
- 18 to 75 years
- Sex
- Men and women can both join.
- Disease stage
- Solid tumor confirmed by tissue examination, or suspected solid tumor seen on imaging. Cancer types listed include urothelial, bladder, prostate, lung, nasopharyngeal, liver, bile duct, ovarian, cervical, endometrial, thyroid, and head and neck cancer.
Main reasons for not taking part
- Pregnancy
- Severe liver or kidney failure
- Allergy to single-domain antibody radiopharmaceuticals
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06851663, who can take part
Where in China
- Renji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, ChinaContact: Weijun WeiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT06851663
- Record updated
- 29 May 2026
- Original description
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.Read full original descriptionShow less
Trop2-targeted immunoPET Imaging of Solid Tumors
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.
Inclusion: Aged 18-75 year-old and of either sex; Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging; Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
Exclusion: Severe hepatic and renal insufficiency; Allergic to single-domain antibody radiopharmaceuticals; Pregnancy；.